• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

ERJ Open Res . Pulmonary function test and computed tomography features during follow-up after SARS, MERS and COVID-19: a systematic review and met

tetano

Editor, Senior Moderator
ERJ Open Res


. 2022 May 30;8(2):00056-2022.
doi: 10.1183/23120541.00056-2022. eCollection 2022 Apr.
Pulmonary function test and computed tomography features during follow-up after SARS, MERS and COVID-19: a systematic review and meta-analysis


Christopher C Huntley[SUP] 1 2 [/SUP], Ketan Patel[SUP] 2 3 [/SUP], Shahnoor-E-Salam Bil Bushra[SUP] 4 [/SUP], Farah Mobeen[SUP] 3 [/SUP], Michael N Armitage[SUP] 5 [/SUP], Anita Pye[SUP] 2 [/SUP], Chloe B Knight[SUP] 4 [/SUP], Alyaa Mostafa[SUP] 4 [/SUP], Marie Kershaw[SUP] 3 [/SUP], Aishah Z Mughal[SUP] 4 [/SUP], Emily McKemey[SUP] 3 [/SUP], Alice M Turner[SUP] 2 3 [/SUP], P Sherwood Burge[SUP] 1 [/SUP], Gareth I Walters[SUP] 1 2 [/SUP]



Affiliations

Abstract

Background: The COVID-19 pandemic follows severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronavirus epidemics. Some survivors of COVID-19 infection experience persistent respiratory symptoms, yet their cause and natural history remain unclear. Follow-up after SARS and MERS may provide a model for predicting the long-term pulmonary consequences of COVID-19.
Methods: This systematic review and meta-analysis aims to describe and compare the longitudinal pulmonary function test (PFT) and computed tomography (CT) features of patients recovering from SARS, MERS and COVID-19. Meta-analysis of PFT parameters (DerSimonian and Laird random-effects model) and proportion of CT features (Freeman-Tukey transformation random-effects model) were performed.
Findings: Persistent reduction in the diffusing capacity for carbon monoxide following SARS and COVID-19 infection is seen at 6 months follow-up, and 12 months after MERS. Other PFT parameters recover in this time. 6 months after SARS and COVID-19, ground-glass opacity, linear opacities and reticulation persist in over 30% of patients; honeycombing and traction dilatation are reported less often. Severe/critical COVID-19 infection leads to greater CT and PFT abnormality compared to mild/moderate infection.
Interpretation: Persistent diffusion defects suggestive of parenchymal lung injury occur after SARS, MERS and COVID-19 infection, but improve over time. After COVID-19 infection, CT features are suggestive of persistent parenchymal lung injury, in keeping with a post-COVID-19 interstitial lung syndrome. It is yet to be determined if this is a regressive or progressive disease.
 
Back
Top Bottom